Par-4 and Telomere-telomerase System in Type 2 Diabetes Patients Who Received GLP-1 or Metformin Treatment

Sponsor: Third Military Medical University
Study ID: NCT02535299
Phase: PHASE4
Status: Unknown

Conditions

GLP-1；Metformin；Telomere-telomerase System；Par-4

Eligibility Criteria

Sex: ALL
Age: 18 Years - 75 Years
Healthy Volunteers: Accepted

Interventions

Liraglutide — DRUG
GLP-1 analog (1.2mg-1.8mg/day) treatment for 6 months
Metformin — DRUG
Metformin(1500mg-2000mg/day) treatment for 6 months

Study Details

Objectives: To investigate the treatment effect between insulin,metformin and Liraglutide; in Type 2 Diabetes in our hospital, in order to investigate the possible mechanism about telomere-telomerase system and Par-4.

Key Dates

Start date: Jun 30, 2016
Status verified: Sep 2016
Primary completion: Dec 31, 2018
Completion: Dec 31, 2019

Study Design

Enrollment: 200 participants (estimated)
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Arms

Experimental: insulin
basic insulin treatment：glargine 10-30 units once a day based on the glucose control for 6 months.

Primary Outcome Measure

physiological parameter:glycosylated hemoglobin A1c [ Time Frame: up to 6 months; ]